Acupressure for Peripheral Neuropathy
Trial Summary
What is the purpose of this trial?
The proposed randomized control trial will evaluate auricular point acupressure (APA) on chemotherapy-induced neuropathy (CIN), rigorously considering point specificity and placebo effects by integrating self-report measures, psychophysical measures (QST), endogenous biomarkers (cytokines), and neuro-imaging to investigate APA's efficacy and underlying mechanism(s).
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you cannot participate if you are using an investigational agent for pain control or have an implantable drug delivery system.
What data supports the effectiveness of the treatment Auricular Point Acupressure for Peripheral Neuropathy?
Research shows that Auricular Point Acupressure (APA) has been effective in reducing pain for conditions like chemotherapy-induced neuropathy and chronic low back pain. In a study on chronic low back pain, participants who received APA reported a 41% reduction in worst pain compared to only 5% in a sham group, suggesting potential benefits for managing peripheral neuropathy as well.12345
Is auricular point acupressure safe for humans?
How is the treatment Auricular Point Acupressure different from other treatments for peripheral neuropathy?
Auricular Point Acupressure (APA) is unique because it involves stimulating specific points on the ear without needles, unlike traditional acupuncture. This needleless approach is designed to manage symptoms like pain and discomfort, and has been studied for its effects on brain activity and pain relief in conditions like chemotherapy-induced neuropathy.13457
Research Team
Constance Johnson, PhD, MS, RN
Principal Investigator
The University of Texas Health Science Center, Houston
Nada Lukkahatai, PHD, MSN, RN
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for cancer patients over 18 who've finished chemotherapy with specific drugs at least three months ago and are experiencing moderate to severe neuropathy pain or numbness. It's not for those using investigational pain agents, drug delivery implants, have latex allergies, prior neurolytic treatments, or pre-existing conditions causing similar symptoms.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive auricular point acupressure (APA) or virtual APA (vAPA) for chemotherapy-induced neuropathy management
Follow-up
Participants are monitored for changes in pain severity, numbness, tingling, and physical function
Treatment Details
Interventions
- Auricular Point Acupressure
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Texas Health Science Center, Houston
Lead Sponsor
M.D. Anderson Cancer Center
Collaborator
National Cancer Institute (NCI)
Collaborator
Johns Hopkins University
Collaborator
University of Texas
Collaborator